NCT05466149View on ClinicalTrials.gov

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2026

Conditions
NSCLC
Interventions
DRUG

Furmonertinib

240mg QD on a continuous dosing schedule.

Trial Locations (1)

130000

Jilin Province Cancer Hospital, Changchun

Sponsors
All Listed Sponsors
lead

Allist Pharmaceuticals, Inc.

INDUSTRY